Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional) | PAR 25 282

Frequently Asked Questions (FAQs)

What is the NIH funding opportunity PAR-25-282 about?

PAR-25-282, titled "Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional)," supports early-stage, exploratory translational research aimed at understanding why mood and psychotic symptoms can first appear, worsen, or change during the menopause transition. The goal is to produce mechanistic insight that can guide future intervention development by identifying concrete biological and behavioral targets.

What is the primary goal of this NOFO?

The central goal is to generate mechanistic understanding of mood and psychosis symptom risk and expression during the menopause transition, in ways that point to modifiable biological and behavioral pathways that could be targeted in later intervention development.

What kinds of mental health conditions are specifically highlighted?

The opportunity highlights conditions and symptom patterns relevant to midlife and the menopause transition, including perimenopausal depression, generalized anxiety disorder, bipolar disorder, schizophrenia, and clinically meaningful subthreshold symptom patterns.

Are subthreshold symptoms in scope, or only full diagnoses?

Subthreshold but clinically meaningful symptom patterns are explicitly included, not only full syndromal diagnoses.

What does NIH mean by "translational" and "mechanism-focused" in this context?

In this NOFO, translational and mechanism-focused research emphasizes connecting real-world clinical phenomena observed in midlife individuals to underlying neurobiology and behavior. Projects are expected to go beyond description by testing hypotheses that link menopause-related changes (for example, endocrine changes) to neural, behavioral, physiological, or other mechanistic pathways relevant to mood and psychosis symptoms.

Are purely descriptive or observational symptom surveys a good fit?

The NOFO emphasizes innovative, hypothesis-driven projects that connect clinical phenomena to underlying neurobiology and behavior rather than purely descriptive studies. Descriptive work alone, without a mechanistic and hypothesis-driven framework, is not aligned with the stated priorities.

How does the NOFO frame "real-world clinical presentations" during midlife?

The NOFO prioritizes work that reflects the complexity of how symptoms present in clinical settings during midlife, including overlapping menopause-related symptoms and psychiatric symptoms. It encourages studies that improve diagnostic clarity and characterization of symptom profiles across menopausal stages.

What menopause-related symptoms are considered important to study alongside psychiatric symptoms?

The opportunity specifically notes hallmark menopause-related symptoms such as hot flashes, night sweats, and sleep disturbance, and encourages examining how these symptom clusters interact with depressive, anxiety, bipolar, or psychosis-related symptoms to influence distress, impairment, and diagnostic clarity.

Why is symptom overlap and misattribution emphasized?

The NOFO highlights that symptoms like sleep disruption may arise from vasomotor symptoms (for example, hot flashes and night sweats) or from psychiatric conditions (for example, depression or mania). Carefully parsing overlap and potential misattribution is encouraged to improve differential diagnosis, staging, and interpretation of clinical symptom change across the menopause transition.

Does the NOFO encourage research on differential diagnosis and staging?

Yes. It encourages careful attention to differential diagnosis and staging, including work that improves identification or characterization of mood and psychosis symptoms by menopausal stage and clarifies how symptom profiles shift across the transition.

What biological factors are especially emphasized?

A key emphasis is on reproductive steroids and related physiological changes during the menopause transition. The NOFO encourages examining how hormone fluctuations or declines, and downstream signaling pathways, may influence systems tied to mood, cognition, perception, and behavior.

What kinds of mechanisms or systems might applicants link to menopause-related endocrine change?

The NOFO names multiple plausible systems, including stress responsivity, neural circuitry, neurotransmission, inflammation, and sleep-wake regulation, among other pathways plausibly linked to depression, anxiety, bipolar symptoms, and psychosis-related experiences.

What does it mean to "bridge levels of analysis" in this NOFO?

Bridging levels of analysis refers to linking measures across domains, such as endocrine measures (for example, hormone levels or patterns) to neural or behavioral readouts, with the aim of identifying candidate mechanisms of action or isolating modifiable pathways that could later be targeted by interventions.

Is intervention development required under this opportunity?

No. The stated purpose is to generate mechanistic insight that can inform future intervention development. The work is positioned as early-stage and exploratory, intended to point toward future pharmacologic, behavioral, device-based, or combined interventions rather than requiring an intervention to be developed within the R21 project itself.

Are clinical trials allowed under this funding opportunity?

Yes. Clinical trials are optional. Applicants may propose mechanistic clinical studies with or without an intervention component, as long as the work aligns with translational, mechanism-focused aims.

What does "Clinical Trial Optional" imply for applicants?

It means applicants may submit projects that include a clinical trial component or projects that do not include a clinical trial component, provided the proposed research remains aligned with mechanistic, hypothesis-driven translational goals related to mood and psychosis symptoms during the menopause transition.

What is the R21 mechanism and why is it used here?

This opportunity uses the NIH R21 mechanism, which is generally intended to support exploratory and developmental research. It is well-suited for piloting innovative approaches, testing novel mechanistic hypotheses, establishing feasibility, or generating preliminary data that can justify larger subsequent studies (such as larger trials or longitudinal work).

What kinds of psychosocial factors does the NOFO encourage applicants to include?

The NOFO encourages incorporating midlife psychosocial factors that may intensify during this period, including caregiving stress, occupational strain, relationship changes, health comorbidities, and accumulated adversity. These variables are encouraged to be integrated into explanatory models when relevant, particularly when they interact with biological changes to affect symptom risk, onset, recurrence, or severity.

Are psychosocial variables treated as secondary or optional background context?

The NOFO indicates an interest in moving beyond treating psychosocial variables as background noise. When relevant, applicants are encouraged to integrate them into mechanistic or explanatory models, especially in combination with biological changes.

Is interdisciplinary collaboration encouraged?

Yes. The NOFO strongly encourages interdisciplinary collaboration and notes that progress may require teams spanning psychiatry, neuroscience, endocrinology, gynecology, sleep research, epidemiology, psychology, and related disciplines.

What review priorities are emphasized in the NOFO description provided?

Review is expected to prioritize the strength and clarity of a hypothesis-driven approach and the depth and coherence of the proposed neurobiological and mechanistic framework explaining mood and psychosis symptoms during the menopause transition.

Who is eligible to apply?

Eligibility is broad and includes many organization types, such as state, county, city, and special district governments; public and state-controlled and private institutions of higher education; independent school districts; federally recognized tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status; for-profit organizations (other than small businesses) and small businesses; and other eligible entities.

Are specific institution types explicitly called out as eligible?

Yes. The announcement calls out additional eligible applicants including Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities, Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions, faith-based or community-based organizations, regional organizations, non-U.S. (foreign) entities, and U.S. territories or possessions.

Can non-U.S. (foreign) organizations apply?

Yes. Non-U.S. (foreign) entities are explicitly listed among eligible applicants.

Is this opportunity limited to academic institutions?

No. Eligibility includes a wide range of entities beyond universities, including governments, nonprofits, for-profits, small businesses, tribal organizations, housing authorities, school districts, and other eligible organizations.

What is the funding agency and program area?

The funding agency is the National Institutes of Health (NIH). The opportunity is categorized as a discretionary NIH grant in the health area.

What CFDA numbers are associated with this opportunity?

The opportunity is associated with CFDA numbers 93.242 and 93.313.

What is the listed closing date and creation date?

The original closing date is listed as January 7, 2028, and the creation date is November 22, 2024.

What kinds of outcomes or deliverables would fit the intent of an exploratory R21 in this area?

Based on the NOFO description provided, a good fit would be generating mechanistic insight, identifying candidate mechanisms of action, linking endocrine change to neural/behavioral readouts, establishing feasibility of innovative approaches, and producing preliminary data that can support larger subsequent trials or longitudinal studies focused on interventions or more definitive mechanistic testing.